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Blood levels of testosterone de-
cline with age in most men, even in
those who are healthy, and this decline
probably begins around the age of 30.
The rate of decline varies greatly be-
tween individuals, and most of the data
are to be found in studies of Cauca-
sian men; both cross-sectional and lon-
gitudinal studies confirm this decline1-
3
. Decreased production of testosterone
by the testes is the main reason for the
lower testosterone levels in older men4.
From a clinical standpoint, the perti-
nent question is whether this decline
in testosterone is significant enough
for many older men to consider testo-
sterone replacement therapy.
In the younger adult hypogonadal
male, there are a number of detrimen-
tal changes in the organs and their
functions accompanying the normal
aging process that might be positively
influenced by Hormone Replacement
Therapy (HRT) (Table 1)2-15. Among
these age-related changes are a de-
crease in muscle tissue mass and a de-
cline in muscle strength5,6, an increase
in body fat, a decline in bone mass,
and an increased incidence of oste-
oporosis and minimal trauma frac-
tures7-9, as well as a decline in the qual-
ity and quantity of sexual thoughts
and enjoyment10. In older men, these
changes may be caused by chronic ill-
ness, medications, and other hormone
deficiencies, but it is also possible that
many of these could be exacerbated by
a relative testosterone deficiency. It is
important to note here that in the
younger adult hypogonadal male,
treatment with androgens is absolutely
justifiable, not being a matter of ques-
tion. The question is whether hor-
mones in older men should be re-
placed or whether hormones in men
with age-related gonadal deficiency
should be replaced.
Although not all of the possible
benefits and risks of HRT have been
established, on the basis of our present
knowledge of the action of testoster-
one, the effects of replacement therapy
in young hypogonadal adult men, and
the outcomes of clinical experience
and studies, a list of such benefits and
risks can be compiled (Table 2)2-40.
Furthermore, at the present time,
there is no agreement as to which hor-
monal or clinical criteria should be
used to decide which older men might
be candidates for HRT, although there
have been several consensus groups
convened to establish such criteria.
There are a number of reasons for this
failure of consensus, including: 1) lack
of simple measurements or findings
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that would classify an older man as be-
ing “testosterone deficient”; 2) disa-
greement as to which hormonal meas-
ure or measures are the most appropri-
ate to use in screening older men for
testosterone deficiency; 3) little or no
data regarding organ-specific testoster-
one dose response in the older man,
and 4) absence of large prospective
randomized male HRT clinical trials
evaluating clinical outcomes. In addi-
tion, it has not yet been established
whether the mode or dose of testoster-
one used for replacement therapy will
affect outcomes. These issues must be
kept in mind when evaluating the cur-
rent data on benefits and risks of tes-
tosterone replacement in older men.
CARDIOVASCULAR EFFECTS
As noted in Table 2, the potential
effect of HRT on cardiovascular dis-
ease is listed both in the benefits and
risks columns. In the past, androgens
have been classified as a potential ad-
verse factor with regard to cardiovas-
cular disease because of the fact that
men are more likely to develop cardio-
vascular disease than women of the
same age. However, this may just mean
that women are better protected from
cardiovascular disease. A historical re-
view has demonstrated that the life ex-
pectancy of castrated male opera sing-
ers was similar to that of intact male
singers16. Studies in young men have
demonstrated that testosterone causes
a lowering in HDL-cholesterol, and in
some cases, an increase in LDL-choles-
terol. On the other hand, epidemio-
logical studies have reported that men
with lower serum testosterone levels
are more prone to heart disease17.
Short-term studies have shown that in
men with known cardiovascular dis-
ease who are given intravenous testo-
sterone, ischemia takes longer to de-
velop during exercise testing18. Fur-
thermore, testosterone infused into
coronary arteries seems to have a
vasodilatory effect19. Testosterone has
been shown to increase fibrinolysis and
lower triglyceride levels.
Although HRT may cause a tempo-
rary state of fluid retention, as yet no
reported cases of exacerbation of hy-
pertension or congestive heart failure
in older men during such therapy have
occurred. A decline in lipoprotein(a)





young hypogonadal men has been
shown to increase libido and the fre-
quency of sexual activity21. Some
studies have shown that testosterone
positively affects well-being and mood
in hypogonadal young men21,22. Lower
serum bioavailable testosterone levels
were found to be associated with de-
pressed mood in a large cross-sectional
study of older men23.
The study of testosterone in depres-
sion was prompted by the observation
that in castrates and hypogonadal men
treated with androgen, the incidence of
depressed mood and emotional insta-
bility decreased. In comparison to
healthy controls, depressed patients had
30% lower levels of total and free tes-
tosterone, while estradiol showed an in-
crease of about 50%. Although some
data suggested a dysfunction of the
hypothalamo-pituitary-gonadal axis,
the majority of researchers concluded
that there appears to be no major
dysregulation of the axis activity in
male endogenous depressives, even if
dysregulation might be related to the
reduced energy levels and sexual appe-
tite occurring in many depressive men21-
25
. Studies in older men with low libido
have generally reported an improve-
ment in libido with testosterone
therapy24,25. Several studies also have
evaluated the effect of HRT on mood
in a blind placebo-controlled manner
and have demonstrated a positive im-
pact26-28.
Table 1 - Changes in some androgen target organs with normal aging and with
Hormonal Replacement Therapy (HRT) in young hypogonadal men.
Target organ Changes seen Changes seen with Hormonal
with aging Replacement Therapy in
hypogonadal men
Muscle mass ↓ ↑
Muscle strength ↓ ↑
Fat mass ↑ ↓
Bone mineral density ↓ ↑
Libido ↓ ↑
Sense of well-being / improved mood ↓, ↔ ↑
Table 2 - Potential benefits and risks of Hormonal Replacement Therapy in older
men.
Benefits Risks
Preserve/Improve bone mass and prevent fractures Retain fluid
Increase muscle mass and strength Precipitate or worsen sleep apnea
Improve physical functions Develop gynecomastia
Decrease cardiovascular disease risk Produce polycythemia
Improve libido Increase cardiovascular benign risk
Improve well-being and mood Hasten development of benign or
malignant prostate disease
Improve aspects of cognition
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COGNITIVE FUNCTION
The relationship between testoster-
one and cognitive function is not clear
due to a paucity of data, the many dif-
ferent cognitive processes that can and
have been assessed, and the timing of
androgen exposure in terms of the sub-
jects’ ages. In one published study on
HRT in older men, there was no change
in tested memory during testosterone
treatment29.
SLEEP APNEA
Testosterone appears to play a role
in the pathogenesis of obstructive
sleep apnea, a disease particularly
prevalent in middle-aged and older
men. Although the incidence of HRT-
induced sleep apnea may not be high,
physicians should be sensitive to this
potential problem and evaluate for
sleep apnea by case history prior to the
initiation of HRT. Testosterone therapy
can worsen sleep apnea in some
hypogonadal men, and the treatment
of sleep apnea may raise low serum tes-
tosterone levels30,31. Although the in-
cidence of testosterone-induced sleep
apnea is unknown, in a recent study
evaluating 54 older men on testoster-
one for 3 years, no increase in apneic
or hypoapneic episodes during sleep
while on therapy was demonstrated32.
GYNECOMASTIA
Tender breasts and gynecomastia
occur in a small proportion of older
men on HRT11-15. A relatively greater
percentage increase in serum estrogen
levels as compared to serum testoster-
one levels may contribute to the
changes in the breasts. While the inci-
dence of gynecomastia in patients with
advanced prostate cancer treated with
estrogens might be reduced with local
radiotherapy performed before the
treatment, this adverse effect can often
be overcome with a downward adjust-
ment in the testosterone dose.
POLYCYTHEMIA
Androgens have been shown to
stimulate red blood stem cells and con-
sequently the production of erythro-
poietin. Even though the coexistence
of sleep apnea and elevated body mass
index may contribute to the develop-
ment of polycythemia, this did not oc-
cur in many of the men studied32-37.
Hormonal replacement therapy in
older men can often result in a signifi-
cant increase in red blood cell mass
and hemoglobin levels. The increases
reported are much larger than those
seen when young hypogonadal men
are given testosterone replacement.
Occasionally, significant poly-
cythemia may result in calling either
for reconsideration of the therapy or a
decrease in testosterone dose. The pat-
tern of testosterone replacement may
affect the magnitude of the change in
red blood cell mass. Those methods
that give a more uniform level of tes-
tosterone within a physiological range
throughout the dosing period demon-
strate a smaller increase in red cell
mass (Table 3).
PROSTATE
Androgens are involved in the
growth of both benign prostate nodule
and prostate carcinoma, although
whether they play a major role in the
initiation of either disease is unclear.
Whether male HRT will increase the
risk of developing clinically signifi-
cant prostate disease in men without
established prostate cancer or with few
or no symptoms of urinary outlet ob-
struction due to an enlarged prostate
is a different question and one for
which no solid data are available4,38-40.
Androgen deprivation can cause re-
gression in both these prostate dis-
eases, and the presence or history of
prostate cancer is an absolute contrain-
dication for the initiation of HRT.
Of the studies reporting PSA values,
most reported no increase with testoster-
one treatment. Of the studies that did
show a statistically significant increase
in PSA, the PSA varied from 0.41 ng/
mL to 0.84 ng/mL1,3,4,10,13,39,40. Also, the
PSA velocity varied from 0.23 ng/mL/
year to 0.52 ng/mL/year, well within the
normal range of accepted yearly change
(<0.75 ng/mL/year) for men not on tes-
tosterone1,3,4,39,40. There has been no re-
ported increase in the incidence of pros-
tate cancer in any HRT trials. In none
of the studies reporting on testosterone
therapy that evaluated parameters such
as prostate size, prostate symptom score
(IPSS), urine flow rates, and urinary re-
sidual volumes was any change in these
parameters noted1,4,29.
While these data on testosterone
therapy and the prostate are encourag-
ing with regard to the risk of such
therapy in the short term, the long-term
effects on the prostate of HRT are still
unknown. Appropriate pretreatment
screening for prostate cancer or signifi-
cantly symptomatic benign disease
prior to initiation of HRT, as well as the
regular monitoring for development of
such disease during therapy, are war-
ranted.
Table 3 - Hemoglobin and hematocrit (Hct) changes in older men on testosterone
(TE) replacement therapy.
Treatment regimen Hemoglobin mean % Men developing
% change Hct>52%
300 mg/3 weeks 20 60
200 mg/2 weeks (average) 5 to 12 (9) 1524-30 (26)
100 mg/week (average) 5 to 12 (8) 15 (15)
 Scrotal patch 2 to 6 0-6
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EFFECTS ON BONE
Hypogonadism is associated with
a reduction in bone mass and is con-
sidered to be the cause of male oste-
oporosis7. Men who are physically or
chemically castrated in adult life dem-
onstrate significant declines in bone
mineral density, while elderly men
who are hypogonadal are at increased
risk for minimal trauma hip fracture.
Because male osteoporotic fractures
are becoming a more prevalent prob-
lem as men live to older ages, if HRT
were to prevent or increase bone min-
eral density in older men and, in turn,
lead to a decrease in fracture number,
this would have significant clinical
impact. Studies of testosterone replace-
ment in young to middle-aged
hypogonadal adult men have gener-
ally demonstrated an increase in bone
mineral density with therapy8,9,41,42.
There have been at least 3 peer re-
viewed articles that have evaluated the
effectiveness of testosterone replace-
ment on bone mineral density in older
men with relative “testosterone defi-
ciency”5,6,32. The findings of these stud-
ies, which have ranged in duration of
testosterone use from 6 to 60 months,
have generally shown an increase in
lumbar spine bone mineral density, al-
though in at least 1 study, this oc-
curred only in those men with the low-
est baseline testosterone32. Less than
half of the studies that evaluated bone
mineral density at other sites showed
an increase at those sites5-9,32,41,42. Be-
cause testosterone is converted to
estradiol in vivo, and because older
men receiving HRT often show a pro-
portional increase in serum estradiol
levels, it is unclear whether the effect
of testosterone therapy on bone is a di-
rect result of testosterone or a result of
increased estradiol levels, or both.
There are still no data available on the
effect of HRT on fracture incidence.
BODY COMPOSITION,
STRENGTH, AND FUNCTION
Normal male aging is accompanied
by a decrease in muscle mass, a de-
cline in strength, and an increase in
upper and central body fat. Physiologi-
cal replacement of testosterone in
hypogonadal young adult men or
supraphysiological treatment of
eugonadal men may result in increases
in lean body mass, muscle size, and
strength (Table 4)5,6,43-45.
The magnitude of the changes in
muscle are similar for the older men and
the young hypogonadal men, but less
than the changes seen in eugonadal
men given additional testosterone46.
Two studies were published evalu-
ating the effect of HRT on measures of
physical function, which is really the
primary endpoint of clinical interest
with regard to HRT and muscle. One
study showed no effect of HRT on
measured functional outcomes, al-
though men on testosterone perceived
a greater improvement in physical func-
tion than did men on placebo therapy32.
Another study did demonstrate an im-
provement in physical function in those
men receiving testosterone as part of re-
habilitation after extended illness35.
CHOICES OF THERAPY
There are a number of testosterone
therapy delivery systems, each associ-
ated with unique properties as well as
adverse effects. The ideal agent is con-
venient, has predictable pharmacoki-
netics, is safe and inexpensive, and has
low abuse potential47,48.
ORAL
Ninety-eight percent of the oral
17-a alkylated androgens (eg, fluoxy-
mesterone, methyltestosterone,
oxandrolone, and danazol) are com-
pletely metabolized by the liver in a
first-pass effect, therefore decreasing
their efficacy. Although available,
these drugs may cause an increase in
liver enzymes, cholestasis, peliosis of
the liver, and liver tumors, and they
should not be used to treat androgen
deficiency48.
Testosterone has been esterified
with undecanoate acid in position 17a,
avoiding hepatic metabolism by al-
lowing absorption by the lymphatic
system first. The half-life is only 1.5
hours, requiring multiple daily doses
(3 to 4 times a day) to maintain maxi-
mal effect. Subnormal testosterone
levels may occur during the day be-
cause of the amount available for ab-
sorption as well as of patient compli-
ance in taking the medications.
Table 4 - Effect of testosterone replacement therapy in older men on body
composition and strength. Data are given as trend and mean percentage changes.
Study n Length of treatment Body fat Lean mass Strength
(months)
10 8 3 ↔ ___ ↑ (grip)
26 13 3 ↔ ↑ (3.2%) ↔ (grip)
27 31 9 ↓ 6.4%) ↔ —
28 6 1 — — ↑ (LE)
29 17 12 ↔ — ↑ (grip)
32 54 36 ↓ (14%) ↑ (3.8%) ↔ (LE, grip)
35 9 2 — — ↑ (grip)
36 7 3 — ↔ (LE, grip)
37 29 18 ↓ (14%) ↑ (5%) —
↔, no change; ↑, increase; ↓, decrease; grip, strength by hand-held dynamometry; LE, lower
extremity strength, usually by isokinetic testing
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PARENTERAL
Intramuscular injections of long-
acting testosterone esters have been
the mainstay of testosterone replace-
ment for decades. The most common
parenteral preparations are either tes-
tosterone enanthate or cypionate. Both
have similar pharmacokinetics and are
given as intramuscular injections of
200 to 300 mg every 2 to 3 weeks.
These injections result in supra-
physiologic peak levels shortly after
injection, followed by a gradual de-
cline to nadir before the next injection.
These wide and fluctuating ranges in
testosterone levels often cause emo-
tional lability. Though these injec-
tions are inexpensive, the adverse ef-
fects are the painful injection of this
oil-based preparation and the wide
fluctuations in mood.
TRANSDERMAL
As well as being inexpensive,
transdermal therapy is a more physi-
ological approach to testosterone re-
placement46,49. Transdermal patches
are available in both scrotal and
nonscrotal patches. Elemental testo-
sterone is absorbed transdermally to
produce serum testosterone levels
within the normal range and to repli-
cate the diurnal physiologic variation
observed in young men. The hepatic
first-pass metabolism is avoided,
thereby limiting hepatotoxicity.
Patches are available for bedtime use,
with peak testosterone levels being
achieved in the morning between 8:00
and 10:00 AM and a nadir prior to
patch replacement. Evaluation of these
patients should be carried out in the
morning to determine the highest daily
level of serum testosterone produced
by the patch. The scrotal patch requires
weekly shaving, and in individuals
with small testes and inadequate scro-
tal skin, patches are difficult to apply.
The nonscrotal testosterone patches
applied to arm, torso, or thigh skin in-
clude Androderm® (SmithKline
Beecham, Philadelphia) and
Testoderm® TTS (Alza Corp., Vacaville,
CA). The most common side effect of
the dermal patches is dermatitis, often
leading to the discontinuation of the
use of the patch. Pretreatment of the
skin area with 0.1% triamcinolone
cream has proven to be effective in de-
creasing the adverse skin reactions50.
TESTOSTERONE GEL
Androgel® (Unimed, Deerfield, IL)
is a clear, colorless, hydroalcoholic gel
containing 1% testosterone. A daily
application on the shoulder, upper arm,
or abdomen of 5 g of Androgel deliv-
ers 50 mg of testosterone per day, with
approximately 10% of the drug being
absorbed during a 24-hour period. This
gel has been shown to increase lean
body mass, decrease body fat, and im-
prove sexual function, mood, and mus-
cle strength in hypogonadal men, re-
gardless of age51,52. Since the active in-
gredient of this gel is not covered by
a patch, there is a risk of transference
of the testosterone to the partner. The
application site must therefore be cov-
ered with clothes or washed before
contact with another individual during
the first several hours.
MONITORING THE PATIENT
During testosterone replacement,
follow-up is important. The beneficial
effects of therapy should be reviewed
in terms of changes in the clinical
manifestation of hypogonadism. Every
6 months, the efficacy of the treatment
and its adverse effects should be re-
viewed. Total and free serum testoster-
one levels should be checked at 1
month, then every 6 to 12 months af-
terwards. Digital rectal examination
and measurements of PSA should be
performed prior to initiation of andro-
gen replacement, at 3 and 6 months,
and yearly thereafter. Any abnormality
on repeat digital rectal examination,
any elevation of PSA above the age-
specific range, a significant increase in
the velocity of PSA above the age-
specific range, or a significant increase
in the velocity of PSA (> 0.7 ng/ml/
year) requires reassessment of the pros-
tate gland with possible ultrasound and
prostate needle biopsy.
Periodic measurements of hema-
tocrit and total and HDL cholesterol
are recommended (every 3 months).
Osteoporotic elderly should be moni-
tored for bone mineral density prior to
therapy and 1 year thereafter.
For those individuals receiving
transdermal patches or gel, testoster-
one levels should be evaluated at the
time of peak levels in the early morn-
ing. Those receiving parenteral injec-
tions should have their testosterone
measured at the peak, usually within
the first week after the injection, as
well as at the first nadir, just before the
next injection. Older men with de-
creased metabolic clearance of testo-
sterone may need to have their doses
adjusted accordingly.
CONCLUSION
The use of testosterone in older
men has become of increasing interest
to both the medical and lay commu-
nities over the past decade. Even
though the knowledge of the potential
benefits and risks of male HRT has in-
creased dramatically, there is still
much that needs to be determined. Al-
though HRT has resulted in increased
bone mineral density, the impact on
fracture risk is unknown. HRTcan lead
to an increase in muscle mass and a
decline in fat mass, but whether this
translates into significant clinical
changes in strength or function has not
yet been proven. On the other hand,
data continue to accumulate that HRT,
with appropriate patient screening and
monitoring, is relatively safe in the
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short term and that many of these early
possible adverse effects can be man-
aged. Well-controlled large multi-
ening cardiovascular or prostate dis-
ease.
center trials need to be undertaken to
determine whether or not HRT will in-
crease the risk of developing or wors-
RESUMO
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O uso da testosterona em homens
idosos, conhecido como Terapia de
Reposição Hormonal no homem ou
Terapia de Reposição com Andro-
gênios, têm aumentado o interesse
para as comunidades médica e leiga na
última década. Muito embora o conhe-
cimento a respeito dos potenciais be-
nefícios e riscos da Terapia de Repo-
sição Hormonal nos homens tem au-
mentado dramaticamente, ainda exis-
te muito que precisa ser determinado.
Embora existam vários benefícios po-
tenciais da Terapia de Reposição com
Androgênios e dados clínicos relacio-
nados com o uso de tal terapia, não
existem ainda nenhum estudo contro-
lado, randomizado e multicêntrico
avaliando o uso de tal terapia. O obje-
tivo deste artigo é revisar os aspectos
atuais sobre os possíveis riscos e be-
nefícios da Terapia de Reposição com
Androgênios discutindo os estudos
clínicos publicados sobre o assunto.
DESCRITORES: Testosterona.
Androgênios. Hormônios. Idoso. Re-
posição.
REFERENCES
1. Gary A, Berlin JA, Mckinlay J et al. An examination of research
design effects on the association of testosterone and male
ageing: results of a meta-analysis. J Clin Endocrinol Metab
1994; 44: 671-84.
2. Vermeulen A. Clinical Review 24: Androgens in the aging male.
J Clin Endocrinol Metab 1991; 73: 221-4.
3. Harman SM, Metter EJ, Tobin JD et al. Longitudinal effects of
aging on serum total and free testosterone in healthy men. J
Clin Endocrinol Metab 2001; 86: 724-31.
4. Tenover JL. Male hormone replacement therapy including
“andropause”. Endocrinol Metab Clin North Am 1998; 27:
969-87.
5. Bhasin S, Storer TW, Berman N et al. Testosterone replacement
increases fat-free mass and muscle size in hypogonadal men.
J Clin Endocrinol Metab 1997; 82: 407-413.
6. Bhasin S, Storer TW, Berman N et al. The effects of
supraphysiologic doses of testosterone on muscle size and
strength in normal men. N Engl J Med 1996; 335: 1-7.
7. Orwoll ES, Klein RF. Osteoporosis in men. Endocrin Review
1995; 16: 87-116.
8. Stanley HL, Schmitt BP, Poses RM et al. Does hypogonadism
contribute to the occurrence of minimal trauma hip fracture in
elderly men? J Am Geriatr Soc 1991; 39: 766-771.
9. Jackson JA, Riggs MW, Spiekerman AM. Testosterone deficiency
as a risk factor for hip fractures in men: a case-control study.
Am J Med Sci 1992; 304: 4-8.
10. Morley JE, Perry HM, Kaiser FE et al. Effects of testosterone
replacement therapy in hypogonadal males: a preliminary
study. J Am Geriatr Soc 1993; 41: 149-152.
11. Hayes JF. Editorial: Testosterone-fountain of youth or drug of
abuse? J Clin Endocrinol Metab 2001; 85: 3020-3023.
12. Bonaccorsi AC. Andropausa: Insuficiência androgênica parcial
do homem idoso. Uma Revisão. Arq Bras Endocrinol Metab
2001; 45: 123-133.
13. Morales A, Heaton JPW, Carson CC III. Andropause: a misnomer
for a true clinical entity. J Urol 2000; 163: 705-712.
14. McClure DR. Androgen deficiency and the aging male: new urologic
perspectives. Cur Urology Reports 2001; 2 (6): 453-459.
15. Flynn V, Hellstrom WJG. Androgen deficiency in the aging male:
pathophysiology, diagnosis, and treatment alternatives. Cur
Urology Reports 2001; 2 (6): 473-479.
16. Nieschlag E, Nieschlag S, Behre HM. Lifespan and testosterone.
Nature 1993; 366: 215.
17. Phyllips GB, Pinkernell BH, Jing TY. The association of
hypotestosteronemia with coronary artery disease in men.
Arterioscler Thromb 1994; 14: 701-706.
18. Webb CM, Adamson DL, Dezeigler D et al. Effect of acute
testosterone on myocardial ischemia in men with coronary
artery disease. Am J Cardiol 1999; 83: 437-439.
19. Webb CM, MCneill JG, Hayward CS et al. Effects of testosterone
on coronary vasomotor regulation in men with coronary heart
disease. Circulation 1999; 100: 1690-1696.
20. Crook D – Androgens and the risk of cardiovascular disease. The
Aging Male 2000; 3: 190-195.
21. Skakkeback NE, Bancroft J, Davidson JM et al. Androgen
replacement with oral testosterone undecanoate in
hypogonadal men: a double-blind controlled study. Clin
Endocrinol 1981; 14: 49-61.
38
REV. HOSP. CLÍN. FAC. MED. S. PAULO 59(1):32-38, 2004Risks and benefits of hormone replacement therapy in older men
Pasqualotto FF et al.
22. Wang C, Alexander G, Berman N et al. Testosterone replacement
therapy improves mood in hypogonadal men – clinical
research center study. J Clin Endocrinol Metab 1996; 81: 3578-
3583.
23. Barret-Connor E, Von Muhlen DG, Kritz-Silverstein D.
Bioavailable testosterone and depressed mood in older men –
the Rancho Bernardo Study. J Clin Endocrinol Metab 1999;
84: 573-577.
24. Hajjar RR, Kaiser RE, Morley JE. Outcomes of long-term
testosterone replacement in older hypogonadal males: a
retrospective analysis. J Clin Endocrinol Metab 1997; 82: 3793-
3796.
25. Rabijewski M, Adamkiewicz M, Zgliczynski S. The influence of
testosterone replacement therapy on well-being, bone mineral
density and lipids in elderly men. Abstracts of the Second
World Congress on the Aging Male, Geneva, Switzerland,
2000 [Abstract 009].
26. Tenover JS. Effects of testosterone supplementation in the aging
male. J Clin Endocrinol Metab 1992; 75: 1092-1098.
27. Marin P, Holmang S, Gustafsson C, et al. Androgen treatment of
abdominally obese men. Obesity res 1993; 1: 245-251.
28. Urban RJ, Bodenburg YH, Gilkison C et al. Testosterone
administration to elderly men increases skeletal muscle strength
and protein synthesis. Am J Physiol 1995; 269: E820-E826.
29. Sih R, Morley JE, Kaiser FE et al. Testosterone replacement in
older hypogonadal men: a 12-month randomized controlled
trial. J Clin Endocrinol Metab 1997; 82: 1661-1667.
30. Matsumoto AM, Sandlom RE, Schoene JA et al. Testosterone
replacement in hypogonadal men: effects of obstructive sleep
apnea, respiratory drives, and sleep. Clin Endocrinol 1985;
22: 713-721.
31. Santamaria JD, Prior JC, Fleetham JA. Reversible reproductive
dysfunction in men with obstructive sleep apnea. Clin
Endocrinol 1988; 28: 461-470.
32. Snyder PJ, Peachey H, Hannoush P et al. Effect of testosterone
treatment on bone mineral density in men over 65 years of
age. J Clin Endocrinol Metab 1999; 84: 1966-1972.
33. Krauss DJ, Taub HA, Lantiga LJ. Risks of blood changes in
hypogonadal men treated with testosterone enanthate for
erectile dysfunction. J Urol 1991; 146: 1566-1570.
34. Drinka PJ, Jochen AL, Cuisinier M et al. Polycythemia as a
complication of testosterone replacement therapy in nursing
home men with low testosterone levels. J Am Geriatr Soc
1995; 43: 899-901.
35. Bakhshi V, Elliott M, Gentili A et al. Testosterone improves
rehabilitation outcomes in ill older men. J Am Geriatr Soc
2000; 48: 550-553.
36. Clague JE, Wu FCW, Horan MA. Difficulties in measuring the
effect of testosterone replacement. Int J Androl 1999, 22:
261-265.
37. Katznelson L, Finkelstein JS, Schoenfeld DA. Increase in bone
density and lean body mass during testosterone administration
in men with acquired hypogonadism. J Clin Endocrinol Metab
1996; 81: 4358-4365.
38. Tenover JL. Experience with testosterone replacement in the
elderly. May Clin Proc 2000; 75 (suppl): 19-25.
39. Behre HM. Testosterone therapy – effects on prostate and bone.
Aging male 2000; 3: 196-202.
40. Shaneyfelt T, Husein R, Bubley G et al. Hormonal predictors of
prostate cancer: a meta-analysis. J Clin Oncol 2000; 18: 847-
853.
41. Stepan JJ, Lachman M, Zverina J et al. Castrated men exhibit
bone loss: effects of calcitonin treatment on biochemical indices
of bone remodeling. J Clin Endocrinol Metab 1989; 69: 523-
527.
42. Goldray D, Weisman Y, Jaccard N et al. Decreased bone density in
elderly men treated with the gonadotropin-releasing hormone
agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab
1993; 76: 288-290.
43. Behre HM, Kliesch S, Leifke E et al. Long-term effect of
testosterone therapy on bone mineral density in hypogonadal
men. J Clin Endocrinol Metab 1997; 82: 2386-2390.
44. Leifke E, Korner H-C, Link TM et al. Effects of testosterone
replacement therapy on cortical and trabecular bone mineral
density, vertebral body area, and paraspinal muscle area in
hypogonadal men. Eur J Endocrinol 1998; 138: 51-58.
45. Reid IR, Wattie DJ, Evans MC et al. Testosterone therapy in
glucocorticoid-treated men. Arch Intern Med 1996; 156: 1173-
1177.
46. Arver S, Lonn L, Ekstrom U et al. The effects of physiological
androgen replacement in aging diabetic men—a placebo-
controlled study. Abstracts of the Second World Congress on
the Aging Male, Geneva, Switzerland, 2000 [Abstract 008].
47. Zitzmann M, Nieschlag E. Hormone substitution in male
hypogonadism. Mol Cell Endocrinol 2000, 161: 73-88.
48. Cunningham GR. Management of male aging: which testosterone
replacement therapy should be used? Aging male 2000, 3:
203-209.
49. Parker S, Armitage M. Experience with transdermal testosterone
replacement therapy for hypogonadal men. Clin Endocrin
1999, 50: 57-63.
50. Wilson DE, Kaidbey K, Boyke SC et al. Use of topical corticosteroid
pretreatment to reduce the incidence and severity of skin
reactions associated with testosterone transdermal therapy. Clin
Ther 1998, 20: 299-306.
51. Swerdloff RS, Wang C, Cunningham G et al. Long-term
pharmacokinetics of transdermal testosterone gel in
hypogonadal men. J Clin Endocrinol Metab 2000, 85: 4500-
4510.
52. Wang C, Swerdloff RS, Iranmanesh A et al. Transdermal
testosterone gel improves sexual function, mood, muscle
strength, and body composition parameters in hypogonadal
men. J Clin Endocrinol Metab 2000, 85: 2839-2853.
